Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Charles River (CRL) to Build RightSource Lab With New Pact
by Zacks Equity Research
Charles River (CRL) will establish a CGMP testing lab at Wheeler's factory through latest partnership.
Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY24 Outlook
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both segments.
Here's Why You Should Retain DaVita (DVA) Stock for Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to the strength of its DaVita Kidney Care.
Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses
by Zacks Equity Research
Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.
Veeva Systems (VEEV) Extends Tie-Up With Lotus Clinical
by Zacks Equity Research
Veeva Systems (VEEV) expands its partnership with Lotus Clinical to accelerate clinical trials.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE), led by the impressive performance of Plasma and Hospital businesses.
Boston Scientific (BSX) Rises 26.4%: Will the Rally Continue?
by Zacks Equity Research
Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.
Stryker's (SYK) Q Guidance Successful in First Surgery
by Zacks Equity Research
Stryker (SYK) successfully completes first surgical case using its Q Guidance system with Cranial Guidance software. An Early Product Surveillance is underway for the combined technology.
Catalent (CTLT) Expands Its Facility Capabilities in Shiga
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.
Abbott (ABT) Reports Upbeat Cardiomems Sensor Study Result
by Zacks Equity Research
Abbott's (ABT) MONITOR-HF is the third randomized, controlled trial that will provide significant health benefits to indicated heart failure patients.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on strong segmental growth.
Why Is Merit Medical (MMSI) Down 1% Since Last Earnings Report?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Veeva Systems (VEEV) Offerings Adopted by Minaris Regenerative
by Zacks Equity Research
Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid the CDMO to modernize its operations and streamline its quality processes globally.
Medtronic (MDT) to Expand Diabetes Care With New Buyout
by Zacks Equity Research
Medtronic's (MDT) latest acquisition will increase its capacity to assist more individuals with diabetes worldwide within a single, seamless Medtronic support ecosystem.
Here's Why You Should Retain Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on continued growth across the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services.
Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.
Masimo's (MASI) Platform Expansion to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) latest expansion to its HEOS platform will likely revolutionize health and wellness tracking by allowing connected care as consumers become tetherless and smartphone-less.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM), owing to its strong product portfolio.
Thermo Fisher (TMO) Expands Manufacturing Facility in APAC
by Zacks Equity Research
Thermo Fisher (TMO) latest expansion will enable it to better assist clients in accelerating their research, development and marketing of medications and vaccines in the Asia-Pacific region.
Accuray (ARAY) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Accuray's (ARAY) solid product portfolio.
Veeva Systems' (VEEV) New Tie-Up to Improve Clinical Trials
by Zacks Equity Research
Veeva Systems' (VEEV) latest collaboration is expected to advance the patient experience in clinical trials.
ShockWave Medical (SWAV) Hits 52-Week High: Will it Continue?
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.